aleglitazar + ibuprofen

**Aleglitazar + ibuprofen** is a hypothetical or non-standardized combination of two small molecule drugs: aleglitazar, a dual peroxisome proliferator-activated receptor (PPARα and PPARγ) agonist developed for type 2 diabetes and cardiovascular risk reduction, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective cyclooxygenase (COX) inhibitor used to treat pain, fever, and inflammation. Aleglitazar's development was discontinued due to insufficient cardiovascular benefit and PPAR-associated side effects. No branded or generic combination of these two agents is approved or marketed; there is no current evidence supporting a co-formulated product, nor is there a unique disease indication for their joint use. The information here describes a theoretical combination based on the individual pharmacological properties of each agent.[1][3][4][5]